Clinical Trial

The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia

Study acronym: ATLANTIS
Recruiting
View on ClinicalTrials.gov →
Summary
The effect of monoallelic variants in the ALPL gene on the natural course of hypophosphatasia (HPP) in children and adults in Russia (ATLANTIS)
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2026-02-02; most recent amendment 2026-07-17.
Trial Details
NCT Number NCT07390240
Lead Sponsor AstraZeneca
Conditions Hypophosphatasia
Enrollment 55 participants
Start Date 2025-12-29
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20